New Liquid Chromatography Column Separates Challenging Glycans and Glycan Isomers
The growing legion of scientists investigating glycans as disease markers and antibody-based biopharmaceuticals (nearly 800 publications in 5 years) now have an effective new tool for the challenging separations of glycans and glycan isomers. Thermo Fisher Scientific will showcase the GlycanPac AXR-1 column at booth #2441 during Pittcon 2014, being held at McCormick Place in Chicago from 2–6 March.
“Until now, glycan isomers could not be separated by conventional HPLC,” said Ilze Birznieks, product marketing manager, biocolumns, for Thermo Fisher. “This new column helps users achieve greater resolution of glycans using HPLC, providing easier profile characterization. This is useful for characterizing glycans from monoclonal antibodies being developed for therapeutics.”
The GlycanPac AXR-1 columns are designed for excellent resolution of labeled and unlabeled glycans, and are compatible with fluorescence and mass spectrometry detection methods. Mass spectrometry has emerged as a powerful tool for determining the structures of glycans, and this new column is designed to enable researchers to harness the power of high-resolution accurate-mass (HRAM) mass spectrometry at high-throughput rates. This column is designed to separate both labeled and native glycans based on the availability of samples. Native glycan separation allows researchers to eliminate the fluorescent labeling step and increase throughput without eroding performance.
For a closer look at the GlycanPac AXR-1 column, visit Thermo Fisher at Pittcon booth #2441, or for more information, click here.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...